Clinical Trials Logo

Proteus Syndrome clinical trials

View clinical trials related to Proteus Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03094832 Terminated - Clinical trials for PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)

MOSAIC
Start date: May 16, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, Phase 1/2 study of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) (MOSAIC).